O T C
PAOG Publishes 2021 Cannabis Biopharmaceutical Strategic Outlook

  Sandusky, OH, January 14, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today published a management outlook for 2021 on the company’s strategy to develop and monetize the cannabis assets acquired last year.  The strategic outlook is included in its entirety below: PAOG 2021 Cannabis Biopharmaceutical Strategic Outlook PAOG is

PAOG Dividend Update Included In 2021 Cannabis Biopharmaceutical Strategic Update Tomorrow

  Sandusky, OH, January 13, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced the upcoming update covering the company’s 2021 cannabis pharmaceutical and nutraceutical development outlook scheduled for tomorrow, Thursday Jan 14th, 2021, will include an update on the planned PAOG stock dividend to shareholders of Puration, Inc. (OTC

The Cannabis Craze is Back in Gear (NASDAQ: SNDL) (NASDAQ: GRWG) (OTC US: MEDH) (OTC US: CRLBF)

Five more states just moved toward greater legalization of pot in November. And a Biden big blue wave win has now been confirmed and will also possibly usher in a federal decriminalization shift that could spur further changes that benefit current players in the cannabis space. With the bull market in gear, the cannabis space

PAOG Confirms Cannabis Biopharmaceutical Strategic Update Targeting $50 Billion Market Scheduled Thursday Jan 14, 2021

Sandusky, OH, January 12, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today confirmed an update covering the company’s 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2021. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA) and RespRx from Kali-Extracts,

PAOG Cannabis Pharmaceutical and Nutraceutical 2021 Strategy Update Targeting $50 Billion Market Scheduled Thursday Jan 14, 2021

  Sandusky, OH – January 11, 2021 – PAO Group, Inc. (OTC PINK: PAOG) today announced an update covering the company’s 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2021. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA) and RespRx from Kali-Extracts, Inc. (OTC

PAOG Confirms Q4 2020 Revenue From Cannabis Asset Acquisition

  Sandusky, OH, January 8, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today confirmed that the company expects to realize and report in Q4 2020 the first revenue from assets acquired in the course of 2020. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA)

PAOG Takes Major CBD Pharmaceutical Development Step Forward

  Sandusky, OH, January 5, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced a major step forward in the development of a CBD pharmaceutical product. PAOG today announced an engagement with Veristat, Inc., a contract research organization headquartered in Southborough Massachusetts.  PAOG has engaged Veristat to assist in advancing

AMERICAN GREEN (OTC: ERBB) ISSUES STRATEGIC CORPORATE OVERVIEW

  PHOENIX, AZ, December 29, 2020 — OTC PR WIRE — Today American Green (OTC PINK: ERBB) has issued this strategic overview for its shareholders highlighting the following news and events for ERBB in 2020.  American Green received fantastic news in November with the passing of the Prop 207 initiative which included the legalization of recreational cannabis for

PAOG Expects To Report First Post Acquisition Revenue In Q4 2020

Sandusky, OH, December 22, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced that the company expects to realize and report in Q3 2020 the first revenue from assets acquired in the course of 2020. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA) and

PAOG Announces Puerto Rico Consortium For Clinical Investigation Engagement To Advance CBD COPD Nutraceutical Care Solution

  Sandusky, OH, December 17, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC US: PAOG) today announced an engagement with the Puerto Rico Consortium for Clinical Investigation to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary

Recent Posts

Recent Posts

Contact Us

All Rights Reserved © 2019